Conceived as a way to resolve differences between government regulators and academics over the chemical’s effects, the CLARITY-BPA collaboration instead highlights divisions.

Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 

Compared to other drugs, therapeutics given breakthrough status receive FDA approval on the basis of weaker trial evidence, a study finds.

President Trump’s pick, Judge Brett Kavanaugh, has often opposed court involvement in environmental and health regulations.

Medical groups have criticized the legislation, which will give terminal patients access to experimental treatments, as dangerous and unnecessary.

Two patients became legally blind after receiving treatments at the facilities.

The Scientist speaks with a clinical toxicologist to discuss how the supplement acts in the brain and what the agency's declaration means for research.

Spark Therapeutics’s Luxturna would be the first approved therapy in the U.S. that replaces or repairs a defective gene inherited from one’s parents.

Only 12 positions out of 44 have received nominations, and half of Trump’s nominees have strong ties to the industries they would oversee, a new report shows.